Prof. Qin Luo 罗琴
Chief Physician, Professor
Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Malignant tumors with venous thromboembolism, chronic obstructive pulmonary disease, bronchial asthma, and cor pulmonale.
Dr. Luo is Director of the Respiratory and Neurology Department at Affiliated Cancer Hospital of Xinjiang Medical University. With 19 years of experience, Dr. Luo holds an MD and serves as a professor and doctoral supervisor. Research focuses on malignant tumors with venous thromboembolism. Dr. Luo has led one National Natural Science Foundation project and won a Second Prize for Scientific and Technological Progress in Xinjiang Uygur Autonomous Region.
Professional roles
- Member, Youth Committee of Health Management Professional Committee, Chinese Medical Association
- Member, Pulmonary Embolism and Pulmonary Vascular Disease Group, 10th Respiratory Disease Branch, Chinese Medical Association
- Member, Evidence-Based Medicine Group, 7th Clinical Epidemiology and Evidence-Based Medicine Branch, Chinese Medical Association
- Standing Committee Member, Health Management Professional Committee, Xinjiang Medical Association
Name order: in Chinese the family name comes first (Luo Qin). Papers usually list the name as Qin Luo or Luo Q.
Selected publications
17 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Genet, 2025 (senior author): Genome-wide analysis of long non-coding RNAs and mRNAs in lung adenocarcinoma with pulmonary thromboembolism. PubMed 41635573
- Am J Cancer Res, 2023 (senior author): LINC01354 enhances the metastatic ability of gastric cancer cells by adjusting miR-153-5p/CADM2 expression. PubMed 37424819
- Heliyon, 2023 (senior author): MiR-210 regulates lung adenocarcinoma by targeting HIF-1α. PubMed 37215862
- Clin Appl Thromb Hemost, 2023 (senior author): Associations Between Immune-Related Venous Thromboembolism and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. PubMed 37844585
- Clin Appl Thromb Hemost, 2023 (senior author): Profile of Solid Tumor Patients Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study Based on 1482 Cases. PubMed 37062945
- Front Oncol, 2022 (senior author): Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study. PubMed 36300098
- Evid Based Complement Alternat Med, 2021 (senior author): Combined Treatment of Cinobufotalin and Gefitinib Exhibits Potent Efficacy against Lung Cancer. PubMed 34122599
- Cell Reprogram, 2020 (senior author): MiR-142-5p Suppresses Lung Cancer Cell Metastasis by Targeting Yin Yang 1 to Regulate Epithelial-Mesenchymal Transition. PubMed 33270501
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion